Qin Y, Shi Y, Su H, et al. 286PFirst china-manufactured proposed rituximab biosimilar met primary efficacy and safety endpoints in CD20-positive diffuse large B-cell lymphoma (generics). Annals of Oncology 2018; 29(suppl_9).
| 专利申请数量 | PCT申请数量 | 国内外授权专利数量 | 发明专利数量 |
|---|---|---|---|
|
809 |
90 | 134 | 97 |
